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Abstract
Background: Trypanosoma cruzi ribosomal P proteins, P2b and P0, induce high levels of antibodies in patients with chronic
Chagas’ disease Cardiomyopathy (CCC). It is well known that these antibodies alter the beating rate of cardiomyocytes and
provoke apoptosis by their interaction with b1-adrenergic and M2-muscarinic cardiac receptors. Based on these findings, we
decided to study the cellular immune response to these proteins in CCC patients compared to non-infected individuals.
Methodology/Principal findings: We evaluated proliferation, presence of surface activation markers and cytokine
production in peripheral blood mononuclear cells (PBMC) stimulated with P2b, the C-terminal portion of P0 (CP0) proteins
and T. cruzi lysate from CCC patients predominantly infected with TcVI lineage. PBMC from CCC patients cultured with P2b
or CP0 proteins, failed to proliferate and express CD25 and HLA-DR on T cell populations. However, multiplex cytokine
assays showed that these antigens triggered higher secretion of IL-10, TNF-a and GM-CSF by PBMC as well as both CD4+
and CD8+ T cells subsets of CCC subjects. Upon T. cruzi lysate stimulation, PBMC from CCC patients not only proliferated but
also became activated within the context of Th1 response. Interestingly, T. cruzi lysate was also able to induce the secretion
of GM-CSF by CD4+ or CD8+ T cells.
Conclusions/Significance: Our results showed that although the lack of PBMC proliferation in CCC patients in response to
ribosomal P proteins, the detection of IL-10, TNF-a and GM-CSF suggests that specific T cells could have both
immunoregulatory and pro-inflammatory potential, which might modulate the immune response in Chagas’ disease.
Furthermore, it was possible to demonstrate for the first time that GM-CSF was produced by PBMC of CCC patients in
response not only to recombinant ribosomal P proteins but also to parasite lysate, suggesting the value of this cytokine to
evaluate T cells responses in T. cruzi infection.
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Introduction
Trypanosoma cruzi, the etiological agent of Chagas’ disease, affects
approximately 8–10 million people, and its infection is one of the
major human health problems in Central and South America,
being extended now to Europe (especially Spain and Portugal), the
United States, Canada, Japan and Australia [1,2,3]. Upon
exposure to the parasite, the humoral and cellular immune
responses elicited by the host, keep acute parasitemia under
control [4,5]. However, approximately 30–40% of the infected
individuals, several years after initial exposure, develop clinical
symptoms of visceral damage, which may include cardiac lesions,
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digestive alterations or both manifestations (cardiac plus digestive)
[5]. Chronic Chagas’ disease Cardiomyopathy (CCC), the most
frequent and severe consequence of the chronic infection by T.
cruzi, is manifested predominately as an arrhythmogenic cardio-
myopathy [6–9].
Up to now, the mechanisms of the pathophysiology of Chagas’
disease are not completely elucidated and two main hypotheses
have been proposed. The first one is based on the inflammatory
reaction elicited by the parasite leading to tissue damage, while the
second argues for an autoreactive process resulting from an
impaired immune response associated with molecular mimicry
[10–13]. However, it is currently accepted that both mechanisms
are not mutually exclusive and that Chagas’ disease is the result of
both, parasite persistence in the chronic phase and the presence of
autoantibodies/self-reactive T cells to host molecules [14,15]. As
supporting evidence for the autoimmune hypothesis, previous
work in our laboratory demonstrated the presence of circulating
antibodies against ribosomal P proteins of T. cruzi (anti-P Abs) with
agonist-like properties on cardiac receptors in patients with CCC
[16–24]. Those Abs predominantly recognized the C-terminal end
of P2b (peptide R13, EEEDDDMGFGLFD) or P0 proteins
(peptide P015, EEEDDDDDFGMGALF), which bear structural
similarity to the acidic motif, AESDE, located on the second
extracellular loop of the cardiac receptor [19,20,22]. Several
studies including patients with CCC as well as experiments
performed in mice immunized with recombinant P2b or P0
protein demonstrated a correlation between the presence of anti-P
Abs and cardiac disorders [21,22]. These findings were confirmed
by the generation of anti-R13 monoclonal Ab, mAb 17.2, which
not only induce a dose-dependent increase on the beating
frequency of rat cardiomyocytes in culture that is abolished by
bisoprolol, a specific b1-adrenergic receptor antagonist [25], but
also provoke apoptosis in the murine cardiac cell line HL-1 by its
long-lasting b1-AR stimulatory activity [24]. The humoral
immune response against ribosomal P proteins has been largely
studied in patients with CCC; however, little is known about their
recognition by T cells.
Most studies concerning the T cell immune response in Chagas’
disease, have been performed using freshly isolated peripheral
blood mononuclear cells (PBMC) but stimulated with epimastigote
(the replicative form found in the midgut of insect vectors) or
trypomastigote (the infective form found in the bloodstream and
other human extracellular fluids) lysate [26–29]. Few investiga-
tions have been focused on the reactivity of T cells against purified
antigens of the parasite [30–40]. To date, studies performed with
recombinant parasite proteins, such as the cytoplasmatic repetitive
antigen (CRA), B13, trans-sialidase, and paraflagellar rod proteins
on PBMC and cruzipain on T cells lines revealed that patients
with CCC produced significant amount of IFN-c upon stimula-
tion, which is in line with the typical pattern of inflammatory
response described for T. cruzi lysate [34–40]. However, Lorena et
al. also reported that the flagellar repetitive antigen (FRA) induced
proliferation of PBMC by thymidine incorporation, but no
difference was observed in IFN-c and TNF-a secretion between
patients with CCC and non-infected individuals [37]. The aim of
this study was to analyze the cellular immune response developed
in patients with CCC against T. cruzi ribosomal P proteins,
knowing the existence of a cross-reactive component at the
humoral level. The specificity of the response was analyzed by
proliferation and cytokine production using multiplex technology
because it allows to quantify a large spectrum of cytokines in the
same cell culture supernatant. Results showed that T. cruzi
ribosomal P proteins, specifically P2b and the C-terminal portion
of P0 (CP0, 110 aa), did not induce the proliferation of PBMCs
from CCC in a different manner than non-infected individuals.
However, these antigens were able to induce the secretion of IL-
10, TNF-a and GM-CSF by PBMC as well as both CD4+ and
CD8+ T cells in patients with CCC. Surprisingly, ribosomal P
proteins did not stimulate but actually reduced the secretion of
IFN-c in cardiac patients. Furthermore, our results demonstrate
for the first time that GM-CSF is produced in response not only to
parasite lysate but also to ribosomal P proteins. These findings
suggest that GM-CSF production could be included in the future
to evaluate whole parasite and parasite protein specific T cell
responses in Chagas’ disease.
Methods
Ethics statement
The research protocols followed the tenets of the Declaration of
Helsinki and were approved by the Medical Ethics Committee of
Ramos Mejı´a and Ferna´ndez Hospitals. All enrolled patients gave
written informed consent, according to the guidelines of the
Ethical Committee of the Hospitals, before blood collection and
after the nature of the study was explained.
Study population
Patient selection was conducted at the Cardiovascular Division
of the Ramos Mejı´a and Ferna´ndez Hospitals, Buenos Aires,
Argentina. Positive serology for Chagas’ disease was determined
by two or more tests (indirect immunofluorescence, enzyme-linked
immunosorbent assay [ELISA], indirect hemagglutination, or
complement fixation). Patients who had at least two of three tests
were considered positive for Chagas’ disease. Patients underwent a
complete clinical and cardiologic examination that included
medical history, physical examination, electrocardiogram (ECG)
at rest, laboratory and chest X-ray analysis, and echo doppler
cardiography evolution. The exclusion criteria included the
presence of systemic arterial hypertension, diabetes mellitus,
thyroid dysfunction, renal insufficiency, chronic obstructive
pulmonary disease, hydroelectrolytic disorders, alcoholism, history
suggesting coronary artery obstruction and rheumatic disease, and
the impossibility of undergoing the examinations. The study
Author Summary
Chronic Chagas’ disease Cardiomyopathy (CCC) is the most
frequent and severe consequence of the chronic infection
by protozoan parasite T. cruzi. Patients with CCC develop
high levels of antibodies against ribosomal P proteins of T.
cruzi, called P2b and P0. These antibodies can cross-react
with, and stimulate, the b1-adrenergic and M2 muscarinic
cardiac receptors, inducing a functional and pathological
response in cardiomyocytes. In this study, we focused on
the cellular immune response developed by CCC patients
in response to T. cruzi ribosomal P proteins. Peripheral
blood mononuclear cells (PBMC) from CCC patients
stimulated with both proteins neither proliferated nor
induced the expression of activation markers on CD4+ and
CD8+ T cells. However, these cells responded by the
secretion of IL-10, TNF-a and GM-CSF, giving evidence that
there is indeed a pool of specific T cells in the periphery
responsive to these proteins. Interestingly, the cytokines
profile was not related with those described to whole
parasite lysate or other recombinant proteins, suggesting
that each parasite protein may contribute differently to the
complex immune response developed in patients with
Chagas’ disease.
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population consisted of 27 patients who completed the screening
protocol and were diagnosed with Chronic Chagas’ disease
Cardiomyopathy.
Twenty non-infected individuals (NI), within the same age range
(30–70 years old) and showing negative serological tests for
Chagas’ disease, were included as control group.
TSSA recombinant proteins
Due to its predominant clonal proliferation, the T. cruzi species
is composed by multiple strains showing extensive genetic
diversity, which were recently grouped into 6 evolutionary lineages
or discrete typing units (DTUs) known as TcI to TcVI [41].
Gluthatione S-transferase (GST)-fusion proteins bearing the
entire TSSA from Sylvio X-10/1 strain (henceforth TSSA Sy,
representative of TSSA isoforms from DTU TcI parasites) and CL
Brener strain (henceforth TSSA CL, representative of TSSA
isoforms from DTUs TcII/TcV/TcVI parasites) were expressed
in Escherichia coli BL21 strain and purified as described [42].
Briefly, supernatants of bacterial cultures transformed with the
indicated construct were induced for 3 h at 28uC with 0.250 mM
isopropyl—b-D-thiogalactopyranoside, purified by glutathione-
Sepharose chromatography and extensively dialyzed against
PBS. The purity and integrity of GST-TSSA samples was assessed
with silver-stained SDS-PAGE gels [42].
T. cruzi lineage identification by immunophenotyping
Enzyme-linked immunosorbent assay (ELISA).
Polystyrene microplates (Nunc Maxisorp, Roskilde, Denmark)
were coated overnight at 4uC with 1 mg of either GST-TSSA Sy or
GST-TSSA CL protein in 100 mL of carbonate buffer. Additional
wells were coated with recombinant GST expressed and purified
as stated above to detect sera background reactivity. Plates were
washed with TBS and then blocked with TBS containing 4% non-
fat dry milk (TBS-M) for 1 h at 37uC. After washing, 100 mL of
each human serum (dilution 1/100 in TBS-M) was loaded onto
plates and incubated for 1 h at 37uC. After washings with TBS,
plates were incubated with 100 ml of HRP-conjugated goat anti-
human Ig (dilution 1/10,000 in TBS-M) (Sigma, St Louis, MO,
USA). Enzyme activity was revealed with TMB (Sigma, St Louis,
MO, USA) and Optical Density (OD) was read at 450 nm with an
Automated Plate Reader (Molecular Devices, CA, USA). All
samples were tested in duplicate, in two independent experiments.
Sera from 4 non-infected individuals were also included on the
plate to determine the baseline level. Serum samples showing OD
values below NI baseline value + 3 standard deviation (SD) were
considered negative, while those rendering OD values between NI
baseline value + 3 SD and NI baseline + 5 SD were considered
non-conclusive.
Dot blot assays. A 1.5 ml drop with 1 mg of each GST-fusion
protein was applied to a nitrocellulose filter (GE HealthCare,
Uppsala, Sweden), allowed to dry at room temperature, blocked
with TBS supplemented with 5% non-fat dry milk and incubated
for 2 h with serum samples diluted 1/200. Washes were
performed four times with TBS 0.2% Tween 20. Anti-human Ig
Abs conjugated to HRP were diluted 1/5,000, incubated for 1 h in
TBS 5% non-fat milk and revealed using either West-Pico or
West-Fempto (both from Pierce, Rockford, USA) chemilumines-
cent substrates.
Antigens
Whole antigenic lysate from T. cruzi epimastigotes was prepared
as described previously [43]. Briefly, fresh epimastigotes (CL
Brener, DTU Tc VI) cultured in a liquid medium (liver infusion
tryptose), were collected by centrifugation and washed three times
with PBS. After centrifugation at 500xg during 5 min, the
parasites were resuspended in lysis buffer (PBS, EDTA 1 mM,
b-mercaptoethanol 5 mM, 0.1% SDS and protease inhibitors
cocktail) and submitted to three cycles of freezing-thawing. The
parasite lysate was diluted with PBS at 1 mg/ml, filter sterilized on
0.2 mm-pore-size membranes, assayed for protein concentration,
aliquoted, and stored at 280uC until use.
The T. cruzi recombinant proteins selected for this study were
P2b-His and CP0-His; this last one corresponds to the C-terminal
portion of P0 (110 aa). The ribosomal P proteins were obtained
and purified by means as His6-tag as described [44]. The purity
and specificity of the recombinant proteins were analyzed by SDS-
PAGE gels and Western-blot with a pool of chagasic and non-
infected sera. Protein concentration was determined by Bradford
(BioRad, Hercules, CA, USA), using BSA (Sigma, St Louis, MO,
USA) as standard protein.
Peptides were prepared by solid-phase method of Merrifield as
described by Mu¨ller et al. with a semi-automatic multi-synthesizer
NPS 4000 (Neosystem, Strasbourg, France) [45]. Their purity was
assessed by High Performance Liquid Chromatography (HPLC)
and identified by mass spectrometry. Peptide R13
(EEEDDDMGFGLFD) was derived from the 13 C-terminal
amino acids of P2b, P015 (EEEDDDDDFGMGALF) from 15
C-terminal region of P0 protein, and peptide H13
(EESDDDMGFGLFD) was derived from the corresponding
region of mammalian ribosomal P proteins [46]. For ELISA,
these peptides were coupled at a molar ratio of 1:30 to BSA
(Sigma, St Louis, MO, USA) with 0.05% glutaraldehyde as
previously described [45]. The products were assessed by
analytical HPLC and amino acid analysis was used to calculate
the peptide–BSA molar ratio.
Enzyme-linked immunosorbent assay (ELISA)
Microwell plates (Nunc Maxisorp) were coated overnight at 4uC
with 50 ng protein/well of T. cruzi lysate, 2 mg/well of recombi-
nant proteins P2b-His and CP0-His or 2 mM of synthetic peptide
in 50 mL of 0.05 M carbonate buffer pH = 9.6. Plates were washed
with PBS containing 0.1% Tween-20 (PBST) and then blocked
with PBST containing 2.5% non-fat dry milk (PMT) for 1 h at
37uC. After washing, 50 mL of each diluted human serum (dilution
1/200 in PMT) was loaded onto plates and incubated for 1 h at
37uC. Following washing, plates were incubated with 50 ml of
peroxidase-conjugated goat anti-human IgG (dilution 1/3,000 in
PMT) (Sigma, St Louis, MO, USA). Enzyme activity was revealed
with TMB and, OD was read at 415 nm with an Automated Plate
Reader (Molecular Devices, CA, USA). All samples were tested in
duplicate. Sera from 8 non-infected individuals were also included
on the plate to determine the baseline level, as the OD mean value
+3 SD. Antibody level is expressed as Reactivity index which was
determined as the OD mean value of each serum sample/baseline
value.
Cell preparation and proliferation assay
Peripheral blood mononuclear cells (PBMC) were isolated from
heparinized blood by Ficoll-Hypaque density gradient centrifuga-
tion (GE HealthCare, Uppsala, Sweden), washed once and
resuspended in RPMI-1640 medium containing 100 U/ml
penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine and 5%
of AB Rh-positive heat-inactivated normal human serum (Sigma,
St Louis, MO, USA). Cell suspensions (200 ml) were cultured as
triplicates in the presence or absence of different stimuli for 4 or 6
days at a density of 2.56105 cells/well in 96-well sterile plates
(round bottom). Stimuli used in the cultures included T. cruzi
lysate, P2b-His, CP0-His (at a final concentration of 10 mg/ml for
Immune Response against T. cruzi Ribosomal P Proteins
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6 days), peptides R13, P015 and H13 (at a final concentration of
5 mg/ml for 6 days) while PHA (Phitohemaglutinin, Sigma, at a
final concentration of 5 mg/ml for 4 days) was used as positive
control. All concentrations were determined by performing
titration experiments. After the incubation period, cultures were
exposed to 1 mCi/well of 3H-thymidine (3H-TdR, specific
activity, 2 Ci/mmol, Amersham, Arlington Heights, IL) for 6 h
and then harvested on glass fiber filters. The incorporated
radioactivity was determined by liquid scintillation counting. All
cultures were performed in triplicate. Results are expressed as
Stimulation Index, calculated as the mean cpm of stimulated
cultures/mean cpm of non-stimulated (culture medium only)
cultures.
Phenotypic analysis of PBMC
2.56106 cells were cultured in 24-well plates in 1 ml cultures
for 6 days with either medium alone, or T. cruzi lysate, P2b-His,
CP0-His (at a final concentration of 10 mg/ml). After centrifu-
gation, cells were washed, resuspended in ice-cold PBS, stained
for 30 min at 4uC with the following fluorescent-labeled
monoclonal antibodies: allophycocyanin (APC) conjugated
anti-CD3 + phycoerythrin-cyano dye Cy5 (PE-Cy5) conjugated
anti-CD4 + phycoerythrin (PE) conjugated anti-HLA-DR +
fluoresceinisothiocyanate (FITC) conjugated anti-CD25, or APC
anti-CD3 + PE-Cy5 anti-CD8 + PE anti-HLA-DR + FITC anti-
CD25. Cells were then fixed with 4% formaldehyde in PBS and
kept at 4uC until analyzed by flow cytometry. In all cases, 10,000
to 15,000 events in the lymphocyte gate were acquired using a
FACSAria flow cytometer (Becton Dickinson). Phenotypic
analyses were carried out with FlowJo flow cytometric analysis
software (TreeStar), selecting the small lymphocyte population.
PBMC stained with FITC, PE-, APC- and PE-Cy5- labeled Ig
control Abs were included in all experiments for background
fluorescence. All Abs were purchased from BD Biosciences (San
Diego, CA, USA).
Isolation of CD3+CD4+ and CD3+CD8+ T cells from
whole PBMC samples
CD8+ T cells were isolated from PBMC by positive selection
using EasySep CD8 Selection Kit (StemCell Technologies, Inc.,
Vancouver, Canada), while CD4+ T cells were separated
from CD3+CD8neg T cells by negative selection (EasySep
CD3 Selection Kit, StemCell Technologies). The purity of
both populations was assessed by flow cytometry using
specific conjugated mAb (see ‘‘Phenotypic analysis of PBMC’’)
and, it was shown to be higher than 90% for both T cells
subsets.
Cytokine determination by multiplex technology
IL-2, IL-4, IL-10, IL-13, IL-17, IFN-c, GM-CSF and TNF-a
were measured in the supernatants of whole PBMC cultures
stimulated in the presence or absence of the indicated antigens
and collected on days 1, 2 and 6 after stimulation. In addition,
the same cytokines were quantified in cultures of isolated CD4+
or CD8+ T cells (56105 cells) co-cultured with irradiated CD3neg
T cells (ratio 1:1) in the presence or absence of antigen after 6
days of stimulation. Cytokines were measured by using MILLI-
PLEX MAP Human Cytokine/Chemokine Kit (for 8 cytokines)
following the manufacturer’s directions (Millipore, St Charles,
MO) and Luminex instrument and Beadlyte software were used
for analysis. All samples were tested in duplicate. Results are
expressed in ng/ml or Fold increase (FI) which was determined
as [(cytokine in stimulated culture) - (cytokine in NS culture)]/
(cytokine in NS culture), where NS denotes non-stimulated
cultured PBMC.
Data analysis
Statistical analysis was performed with GraphPad Prism
statistical software (GraphPad Software). The nonparametric
Mann-Whitney U test was used to generate P values comparing
the median experimental values between groups each of the
multiple sets of experimental data. Within each experiment,
overall statistical significance of each result at both 10% and
5% significance was determined using Holm-Bonferroni Correc-
tion. Differences were considered statistically significant at P,
0.05.
Results
Characteristics of patients with chronic Chagas’ disease
Cardiomyopathy
Patients included in this study were all born in endemic areas
from Argentina and Bolivia, and at the time of the enrollment they
have been living in Buenos Aires (where no vectorial transmission
occurs) for more than ten years, in average. The mean age was
54.2610.1, and 57% were female.
All T. cruzi-infected subjects were in the chronic phase of
Chagas’ disease, involving only cardiac alterations. According to
the New York Heart Association (NYHA) functional classification
system, patients were classified as Class I, II, III/IV. Patients with
no functional limitations but with some electrocardiographic
alterations were classified as Class 0 [5].
Blood samples yielded negative results for currently used PCR
protocols targeting parasite DNA [47], which is frequently the case
in chronic chagasic patients due to low parasitemia. Taking this
into account, we analyzed the profile of the humoral anti-TSSA
(trypomastigote small surface antigen) response in our study
patients as an indirect means of identifying the genotype of the
infecting strain(s) [48,49]. To carry out this analysis, we evaluated
the reactivity of serum samples against either TSSA Sy (the TSSA
isoform from DTU TcI) or TSSA CL (the TSSA isoform from
DTUs TcII/V/VI) in conventional ELISA and dot-blot (see Text
S1 for details and Figure S1).
The main characteristics of the study population are summa-
rized in Table 1.
Humoral immune response against ribosomal P proteins
To characterize the humoral response in the subject population
included in this study, the antibody reactivity against T. cruzi
lysate, ribosomal P proteins, P2b and CP0, together with their C-
terminal peptides R13 and P015 was determined in sera of CCC
patients and non-infected individuals by ELISA. The reactivity
against peptide H13, which corresponds to the C-terminal region
(residues 102–115) of the human ribosomal P protein was also
measured.
Results showed that sera from CCC patients presented
reactivity against T. cruzi lysate, with titers ranging from 1/200
to 1/20,000 (Table 1). Only patient P19 showed a titer against
parasite proteins similar to those detected in non-infected
individuals (,1/200 at OD = 1). Although antibodies in the
serum sample from this patient were not detected by in-house
ELISA, two of three serological tests for T. cruzi infection, together
with clinical and cardiological examinations confirmed patient P19
to have CCC. In addition, sera of all patients, including P19,
reacted with a broad range of T. cruzi proteins as determined by
Western-blot (data not shown).
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The majority of CCC patients (24/27) showed reactivity
(Reactivity index .1.7) to ribosomal P2b protein and its peptide
R13. The level of anti-CP0 antibodies was also elevated in the
chagasic patients (17/27) compared to non-infected individuals,
but the overall reactivity was lower than that observed for P2b
protein (Figure 1). On the other hand, only marginal
differences were determined in the median of the Reactivity
Index for the anti-P015-antibodies in cardiac patients in
comparison with non-infected subjects. No difference was
observed against peptide H13 (human P ribosomal protein
derived) between both groups of individuals (Figure 1).
Together, these results showed that CCC patients mount a
significant antibody response to ribosomal proteins as well as to
peptides R13 and to a lower level to P015 in comparison to
non-infected subjects.
Patients with chronic Chagas’ disease Cardiomyopathy
and non-infected individuals showed similar proliferative
profiles in response to ribosomal P proteins
In order to investigate the cellular response to ribosomal P
proteins, PBMC from CCC patients and non-infected individuals
were tested for their proliferative capacity in response to different
T. cruzi antigens. To determine the optimal protein and peptide
concentration yielding the most consistent results, the prolifera-
tive response was initially assayed in PBMC cultures from 4
cardiac patients non-included in this study. The results showed
that 10 mg/ml of T. cruzi lysate or ribosomal P proteins and 5 mg/
ml of the peptides were optimal to trigger proliferative responses,
and so these concentrations were used in the studies presented
here.
Table 1. Characteristics of patients with chronic Chagas’ disease Cardiomyopathy.
Patient Code Gendera Age Nationality
Clinical classification
(NYHA)b
T. cruzi Ab level
(1/dilution at OD=1.0)c T.cruzi lineaged
P8 F 63 Bolivia II 200 VI
P10 M 70 Argentina 0 300 ND
P11 M 34 Argentina 0 2,000 VI
P14 F 53 Argentina I 2,000 VI
P19 F 52 Argentina I ,200 ND
P20 F 63 Argentina II 1,600 ND
P21 M 56 Argentina III/IV 4,000 VI
P22 F 53 Bolivia I 2,000 VI
P23 M 42 Argentina I 1,100 I
P24 F 56 Argentina I 4,500 VI
P25 M 47 Argentina II 850 VI
P26 F 62 Bolivia II 26,000 VI
RM1 F 47 Argentina I 4,000 VI
RM2 M 65 Argentina 0 100 VI
RM4 F 52 Bolivia 0 9,500 I
RM5 F 37 Bolivia II 10,000 VI
RM6 F 56 Argentina II 8,000 I
RM7 F 54 Argentina 0 5,000 VI
RM8 F 66 Argentina 0 300 VI
RM9 F 46 Bolivia II 15,000 VI
RM10 M 50 Bolivia 0 7,000 VI
RM11 M 59 Bolivia 0 8,000 VI
RM12 F 67 Bolivia II 500 I-VI
RM13 M 40 Argentina 0 3,000 VI
RM14 F 60 Bolivia II 12,000 VI
RM15 M 64 Argentina 0 2,000 VI
RM16 M 42 Bolivia 0 6,000 VI
aF: female, M: male.
bPatient’s heart failure was classified according to New York Heart Association (NYHA) Functional Classification. Class I: Patients with cardiac disease with slight
functional alterations but resulting in no limitation of ordinary physical activity; however, elevated activity causes symptoms, such as fatigue, palpitation, or dyspnea
(shortness of breath); Class II: Patients with cardiac disease resulting in slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in
symptoms; Class III: Patients with cardiac disease resulting in marked limitation of physical activity; comfortable at rest, but less than ordinary activity causes symptoms;
Class IV: Patients with cardiac disease resulting in marked limitation of physical activity, unable to carry out any physical activity without discomfort; symptoms of
cardiac insufficiency at rest.
Patients with cardiac disease without any functional alteration were classified as Class 0.
cThe level of antibodies directed to T. cruzi lysate was determined by in-house ELISA as described upon Methods.
dT cruzi lineage was analyzed by TSSA recognition as described upon Methods. Results are shown in Figure S1. ND: not detected.
doi:10.1371/journal.pntd.0002906.t001
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As shown in Figure 2, the majority of PBMC from CCC
patients proliferated upon stimulation with T. cruzi lysate
(Stimulation index median: 4.45) compared to PBMC from non-
infected individuals (Stimulation index median: 1.07; P,0.001).
On the contrary, the stimulation index of PBMC from cardiac
patients and control subjects in response to ribosomal P proteins
(Figure 2) as well as to peptides R13, P015 and H13 was not
significantly different (data not shown). PBMC from all subjects
proliferated in response to PHA and the responses were not
significantly different between the cardiac and non-infected
individuals (data not shown).
To characterize the phenotype of the cells after the stimulation
with the different stimuli, cells were stained with different T cell
markers and analyzed by flow cytometry. The forward vs side
scatter dot plots revealed that the frequency of lymphocyte
population in non-stimulated cultures was significantly lower in
cardiac patients compared with non-infected individuals (48613%
vs 62610%, respectively; P,0.001). However, the CD3+CD4+
:CD3+CD8+ ratio was approximately 2:1 in both groups.
Interestingly, results showed that CCC patients present higher
subsets of CD25 and HLA-DR positive cells on both CD3+CD4+
and CD3+CD8+ populations upon T. cruzi stimulation (Figure 3).
However, the expression of these markers was similar in T cells
from cardiac patients and non-infected individuals when cells were
stimulated with ribosomal P proteins (Figure 3).
Cytokine response to ribosomal P proteins
Given the lack of proliferative response to ribosomal P proteins
in the CCC patients, T cell activation was studied by analyzing
cytokine secretion. Thus, PBMCs from 10 cardiac patients with
different disease severity, and 8 non-infected donors were
stimulated with P2b and CP0 proteins and T. cruzi lysate as well
as PHA as positive control. Supernatants after 1, 2 and 6 days
post-stimulation were collected and multiplex analysis was
performed to evaluate the levels of GM-CSF, IFN-c, IL-10, IL-
13, IL-17, IL-2, IL-4 and TNF-a. Despite the fact that cytokine
responses have been studied by others after T. cruzi stimulation in
patients with Chagas’ disease [50,51], reports have used different
assays and stimulation/culture conditions making the direct
comparison of all the cytokines difficult to achieve. In this study,
Figure 1. Humoral response against ribosomal P proteins and their C-terminal peptides. The presence of antibodies directed against P2b
and CP0 proteins as well as peptides R13, P015 and H13 in the sera of 27 patients with chronic Chagas’ disease Cardiomyopathy patients (CCC) and
20 non-infected individuals (NI) was determined by ELISA as described under Methods. Results are expressed as Reactivity index, calculated as:
(Optical Density mean value obtained of each serum sample/baseline value). Each symbol represents data from a single subject. Statistical analysis
was performed using the Mann-Whitney U Test, ***P,0.001, *P,0.05. The line for each of the scatters represents the median.
doi:10.1371/journal.pntd.0002906.g001
Figure 2. Parasite lysate but not ribosomal proteins trigger PBMC proliferative responses. PBMC isolated from chronic Chagas’ disease
Cardiomyopathy patients (CCC; n = 27) and non-infected individuals (NI; n = 20) were seeded at 2.56105 cells/well and stimulated with T. cruzi lysate,
P2b or CP0 proteins (10 mg/ml) or medium alone for 6 days. Cell proliferation was determined by 3H-thymidine incorporation. Results are expressed
as Stimulation index, calculated as: (mean cpm of stimulated cultures/mean cpm of non-stimulated cultures (medium only)). Each symbol represents
data from a single subject. Statistical analysis was performed using the Mann-Whitney U Test, ***P,0.001.
doi:10.1371/journal.pntd.0002906.g002
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Figure 3. Activation markers on CD4+ and CD8+ T cell subsets upon T. cruzi and ribosomal protein activation. PBMC isolated from
patients with chronic Chagas’ disease Cardiomyopathy (CCC; n = 27) and non-infected individuals (NI; n = 20) were seeded at 2.56106 cells/well and
stimulated with T. cruzi lysate, P2b or CP0 proteins (10 mg/ml) or medium alone for 6 days. PBMC were stained with CD3-APC, CD4-PE-Cy5 or CD8-PE-
Cy5 and activation marker-specific labeled antibodies (CD25-FITC and HLA-DR-PE) prior to flow cytometry analysis. 10,000–15,000 events in the
lymphocyte gate (R1 gate) were acquired using a FACSAria flow cytometer (Becton Dickinson); dead cells were excluded by forward vs side-scatter
(FSC/SSC) gating. A) Gate-pathway used to determine the activation expression in the populations graphed in B. B) Results were expressed as the
Immune Response against T. cruzi Ribosomal P Proteins
PLOS Neglected Tropical Diseases | www.plosntds.org 7 June 2014 | Volume 8 | Issue 6 | e2906
we aimed to simultaneously evaluate the kinetic responses of
multiple cytokines in the same culture well. Figure 4 shows the
maximum fold increase detected for each cytokine and in each
subject among day 1, 2 and 6 determinations. The fold increase
was determined by the difference between cytokine production (in
pg/ml) in stimulated wells and the cytokine production in non-
stimulated control wells divided the cytokine production in non-
stimulated control wells. The actual fold increase for each of the
days and the background production in pg/ml of each of the
cytokines in non-stimulated wells are shown in Figures S2 to S5
and S6, respectively.
Upon stimulation with ribosomal P proteins, GM-CSF, IL-10
and TNF-a were secreted at higher levels in cardiac patients
compared with non-infected individuals (Figure 4 and Figure S2
and S3). However, both proteins induced similar levels of IFN-c
production in PBMC from cardiac patients and non-infected
subjects (Figure 4). Furthermore, the fold increase of IFN-c
production in response to both proteins was lower and statistically
significant in the cardiac group after only the first days post-
stimulation (Figure S2 and S3). The level of IL-2, IL-4, IL-13 and
IL-17 secreted after stimulation with the ribosomal P proteins was
very low or null at any of the 3 time points analyzed and, it was
found to be similar between CCC patients and non-infected
individuals (Figure 4 and Figure S2 and S3).
A larger number of cytokines were produced in response to T.
cruzi lysate or the universal stimulus PHA than in response to the
individual ribosomal P proteins (Figure 4). Indeed, PBMC from
cardiac patients in response to T. cruzi lysate also secreted
statistically significant and higher levels of IFN-c, IL-2 and IL-13
compared with non-infected individuals. IFN-c and IL-13 were
also increased in CCC patients vs non-infected individuals when
PHA was used for stimulation. These results indicate that although
the cells were capable of producing IFN-c and IL-13 in response to
whole parasite or PHA, their production was not detected when
the ribosomal P proteins were used as stimulus. The kinetic
cytokine profile for T. cruzi lysate and PHA is shown in Figure S4
and S5.
Profiles of cytokine production by CD4+ and CD8+ T cell
subsets derived from CCC patients
The results presented above revealed a cytokine signature
expression upon stimulation with ribosomal P proteins and T. cruzi
lysate in whole PBMC. To better understand the specific
contribution of the T cells to this profile, CD3+CD4+ and
CD3+CD8+ T cell subsets from three cardiac patients were
enriched from PBMC and stimulated with the antigens in the
presence of autologous antigen-presenting cells. Samples from
patients RM11, RM12 and RM14 were chosen since they were
among those that showed clear cytokines response after ribosomal
P proteins stimulation.
As shown in Figure 5, GM-CSF was overall produced by both,
CD4+ and CD8+ subsets by the 3 patients in response to the
proteins and T. cruzi lysate. In general, IFN-c was produced at
very low levels by CD4+ and CD8+ T cells in all patients in
response to the proteins, but enough to be different from the non-
stimulated wells in the case of CD4+ T cells (Figure 5). IL-10 was
found to be secreted most frequently by both T cell subsets. IL-13
was not produced by CD8+ T cells in any of the 3 patients
analyzed and in response to all the stimuli tested. However, IL-13
was produced by CD4+ T cells in response to T. cruzi lysate and/
or the proteins in the 2 of the 3 patients (RM11 and RM14). TNF-
a was produced by both, CD4+ and CD8+ T cells and its
production was higher in response to the proteins than to T. cruzi
in 2 of the 3 patients. IL-2, IL-4 and IL-17 were not detected in
response to any of the stimuli (data not shown).
Discussion
Since it has been widely demonstrated the relevance of
antibodies directed to ribosomal P proteins in the pathophysiology
of Chagas’ disease [21,23,24], this study aimed to further
understand the cellular immune response raised against these
proteins in CCC patients. Our results showed that PBMC did not
proliferate upon in vitro stimulation with P2b and CP0 proteins.
Additionally, the lack of proliferation in response to the proteins
was associated with the absence of the expression of activation
markers CD25 and HLA-DR on CD4+ and CD8+ T cell
populations. These findings were also protein-specific, since T.
cruzi lysate provoked an augmentation of both markers on the
surface of T cells in agreement with data published by others
[50,51]. Interestingly, the percentage of both T cell subtypes,
CD3+CD4+ and CD3+CD8+ in PBMC were similar in cardiac
patients and non-infected individuals independently of the
stimulus. These results suggest that the lack of proliferative
response was not due to an overall decrease on the size of the T
cell population, nor to a shutdown of the proliferative capacity in
these patients since the same cells responded to T. cruzi lysate and
a T cell specific universal mitogen such as PHA. However, it was
possible to speculate that T cells specific to these proteins have
been deleted by negative selection due to the similarity to the host
specificities. In this regards, the analysis of the T cell response by
cytokine release discarded this possibility since indeed, several
cytokines were expressed in response to ribosomal T. cruzi proteins.
The use of multiplex technology allowed us to simultaneously
analyze 8 cytokines, namely, IL-2, IL-4, IL-10, IL-13, IL-17, IFN-
c, TNF-a and GM-CSF, corresponding to well-described CD4+
and CD8+ associated cytokines. In particular, GM-CSF was
included because not only its production has been associated to
antigen mediated activation of T cells by us and others but also,
the threshold of antigen requirement for its production is lower
than for other cytokines as TNF-a, IL-4 or IFN-c [52–54].
Our results showed that PBMC from CCC patients secreted
high levels of GM-CSF, IL-10 and TNF-a in response to P2b and
CP0 proteins. Interestingly, the secretion of IFN-c at day 1 and 2
post-stimulation with ribosomal P proteins was similar or lower in
cardiac patients vs non-infected individuals. Moreover, our data
demonstrated that patients with CCC developed a different
cytokine profile in response to T. cruzi and PHA stimulation than
non-infected subjects.
Even though the secretion of GM-CSF, IL-10 and TNF-a in
response to the proteins was significantly higher in cardiac vs non-
infected individuals (P,0.05, nonparametric Mann-Whitney U
Test), these P values nonetheless did not stay significant at the 5%
level when a multiple comparison (all 32 cytokine/stimulus
pairings) was performed by using Holm-Bonferroni correction.
In contrast, the P values for these cytokines in response to T. cruzi
lysate did reach statistical significance at the 5% level. This
difference could be explained by the fact that the frequency of
percentage of CD25+ or HLA-DR+ cells in CD3+CD4+ (R2 gate) or CD3+CD8+ (R3 gate) lymphocytes. Horizontal lines represent the median and
percentiles 25–75th, vertical lines represent percentiles 5–95th. Statistical analysis was performed using the Mann-Whitney U Test, ***P,0.001, **P,
0.01, *P,0.05.
doi:10.1371/journal.pntd.0002906.g003
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Figure 4. Cytokine expression in PBMC from chagasic patients after in vitro stimulation. PBMC isolated from patients with chronic
Chagas’ disease Cardiomyopathy (CCC; n = 10) and non-infected individuals (NI; n = 8) were cultured in the presence of the indicated stimulus.
Supernatants were collected on days 1, 2 and 6 and cytokines were quantified by multiplex technology. The Fold increase (FI) was calculated as:
[(cytokine in stimulated culture) - (cytokine in NS culture)]/(cytokine in NS culture), where NS denotes non-stimulated cultured PBMC. The maximum
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single specific parasite protein T cells within the bulk population is
lower than the frequency developed in response to whole T. cruzi
lysate and therefore it leads to lower cytokine secretion levels.
However, it is important to remark that were the P values
distributed at random amongst the proteins data, there would be
only a
8
3
 
16
6
 ~0:7% chance of the three exact same cytokines
(GM-CSF, IL-10 and TNF-a) being secreted in response to both
proteins, demonstrating that the difference observed between
cardiac patients and non-infected individuals was not a mere
coincidence.
Following with T. cruzi lysate response, we observed that all
studied cytokines were elevated and significantly different in the
supernatants of cultured PBMC from cardiac patients with
exception of IL-4 and IL-17. Upon PHA stimulation, PBMC
from cardiac patients secreted higher amount of GM-CSF, IFN-c,
IL-10, IL-13, and TNF-a; similar production was observed for IL-
2, IL-4 and IL-17 between both groups of individuals. In addition,
and independently of the stimulus, our results also showed that
these cytokines were secreted by both T cells populations, except
for IL-13 which was predominantly produced by CD4+ T cells.
Despite this finding, it is well-known that non-T cells, such as
monocytes or B cells, also participate in the secretion of these
cytokines. Indeed, Gomes et al. [28], by intracellular cytokine
staining, reported that the majority of the IL-10-producing cells
are monocytes (CD14+ cells) in asymptomatic patients, and the
same group recently demonstrated that CD19+ B cells is another
important source of this cytokine in cardiac patients [55].
Furthermore, the spontaneous release of cytokines in non-
stimulated PBMC, which provides information about the basal
level of cytokine production in vivo, showed a lower level for IFN-c,
IL-10, IL-13, and TNF-a in CCC patients (Figure S6). It should be
mentioned that Dutra et al. demonstrated that the expression of
IFN-c, IL-10, IL-13 mRNAs was increased in PBMC from
chagasic patients [33]. However, this discrepancy could depend
either on the use of ex vivo PBMC or on the methodology used to
determine cytokine expression. Our data, together with those
reported by Giraldo et al. [56], may suggest that T. cruzi persistence
provokes a general dysfunction in peripheral T cell response.
The high levels of pro-inflammatory cytokines, like IFN-c and
TNF-a, together with undetectable IL-4 production in response to
PHA and T. cruzi stimulation suggest that there is a shift towards
polarized Th1-type of cytokine response in CCC patients.
Although IL-10 was first described related to Th2 cells, now is
known that is produced by all T cells, including Th1 and a
regulatory T cell subsets, called Tr1 cells or IL-10-producing cells
[57]. Recent studies with an experimental murine model revealed
not only the protective role of IL-10 against fatal myocarditis, but
also demonstrated that this cytokine was produced by both CD4+
and CD8+ subsets of IFN-c+IL-10+ double-producing T cells
[58]. Similar data were obtained in studies by Belkaid et al. [59],
where the main source of IL-10 in dermis and draining nodes of
mice infected with Leishmania major is a subset of CD4+ T cells that
produce both IL-10 and IFN-c.
Studies performed with others recombinant parasite proteins
demonstrated that the majority of chagasic patients develop a
strong humoral and cellular immune response with a tendency to
the typical pattern of inflammatory response described for T. cruzi
lysate [34–40]. On the contrary, the cytokines released upon
ribosomal P proteins stimulation made difficult to set a specific Th
cells responsible for their secretion. This mixed cytokine profile
which could be involved in balancing heart tissue damage and
parasite persistence during chronic disease, strengthens in part the
fact that B cells, through antibodies directed against P2b and CP0
and not T cells, would have the major role in the development of
cardiac symptoms by their interaction with b1-adrenergic and M2
muscarinic receptors.
Interestingly, GM-CSF was secreted at high levels by PBMC
from CCC patients when T. cruzi lysate, and both ribosomal P
proteins were used as stimulus. To our knowledge, this is the first
time that GM-CSF is used to evaluate the T. cruzi specific response
of stimulated PBMC from cardiac patients. Instead, GM-CSF has
been associated to a decrease in the rate of infection of both non-
activated and IFN-c activated macrophages infected with T. cruzi
[60]. Moreover, Olivares Fontt et al. reported that the adminis-
tration of exogenous recombinant GM-CSF improved the
deficient immune response of chronically infected mice or, if
neutralized by Ab anti-GM-CSF, it aggravated infection increas-
ing parasitemia and host mortality in T. cruzi infected BALB/c
mice [61]. In the aforementioned report, the role of GM-CSF was
studied by correlating the outcome of infection with the titer of
GM-CSF in plasma levels [61]. Even though it was not defined
which cells were involved in GM-CSF secretion, it was speculated
that lymphocytes could be in part contributing to the low but
sustained amount of GM-CSF levels in infected mice. In our
experiments, CD4+ and CD8+ T cells contributed almost equally
with the secretion of this cytokine, independently of the stimulus,
but it is not possible to discard that other cells as part of the PBMC
pool also produced this cytokine.
While many questions remain regarding the pathogenesis of
Chagas’ disease, this study represents one of the most comprehensive
about the cytokine profile in response to T. cruzi and two
recombinant proteins, like P2b and CP0. The results show that a
pool of PBMC in CCC patients has specificity for T cruzi proteins
and that this specificity is revealed by a Th1-cytokine dominant
milieu, combined with regulatory cytokines like IL-10 and IL-13.
This observation reinforces the idea that a delicate cytokine
equilibrium prevails during the chronic phase of the disease.
Interestingly, another cytokines, namely GM-CSF, were found
significantly increased in cardiac compared to non-infected individ-
uals, tempting us to suggest that this cytokine may be further applied
for studying antigen responses at different stages of the disease.
Finally, due to the limited number of patients infected with TcI
(3/27) compared with TcVI (20/27), it was not possible to
determine a correlation between the intensity of humoral and
cellular immune response and the T. cruzi lineage detected by
TSSA reactivity. Further studies in that sense would provide
valuable information on the role and contribution of genetic
variability of T. cruzi to the immune response developed in
humans.
As a whole, our findings also demonstrate that not all parasite
proteins provoke a strong T cell activation combined with a
pattern of cytokines similar to those described to T. cruzi lysate or
by infection with trypomastigote in CCC patients. In addition, as it
was recently reported in the context of B cell-T cell recognition for
other molecule-specificities [62,63], it is possible to hypothesize
FI out of the 3 day-determinations for each subject and for each cytokine are shown. In color are denoted the cytokines for which the FI in the CCC
patients were statistically significantly higher than in non-infected individuals. Each symbol represents data from a single subject. Statistical analysis
was performed using the Mann-Whitney U Test, ***P,0.001, **P,0.01, *P,0.05.
doi:10.1371/journal.pntd.0002906.g004
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Figure 5. Cytokine production profile by CD4+ and CD8+ T cells derived from chagasic patients. CD4+ and CD8+ T cells from three
chronic Chagas’ disease Cardiomyopathy patients, called RM11, RM12 and RM14, were isolated as described under Methods. Enriched CD4+ or CD8+
T cells were co-cultured with the autologous CD3(neg) fraction as antigen presenting cells and the indicated stimulus. Supernatants were collected on
day 6 and cytokines quantified by multiplex technology. For comparison, results from whole PBMC from each of the patients are represented in the
left panel. Symbol (+) indicates a fold induction between 3 to 5 and (++) a fold induction.5. The fold induction was calculated as: [(cytokine in
stimulated culture) - (cytokine in NS culture)]/(cytokine in NS culture), where NS denotes non-stimulated cells.
doi:10.1371/journal.pntd.0002906.g005
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that B cells specific for ribosomal P proteins could obtain help
from T cells exhibiting different antigen reactivity. However, the
interacting elements for T cell help recognition and activation may
be the same for P2b and CP0, since a positive correlation was
observed between the cytokines secreted by each of them (Figure
S7). Currently, we are in the process of analyzing the
immunoprevalence of recognition of these ribosomal P proteins
and novel specificities involved in the immune response to T. cruzi
infection in a large number of infected subjects at different stages
of the disease.
Supporting Information
Figure S1 T. cruzi immunophenotyping of chagasic
patients using TSSA proteins. The presence of antibodies
directed against GST, GST-TSSA Sy or GST-TSSA CL
proteins was determined by ELISA in chronic Chagas’ disease
Cardiomyopathy patients (CCC) and non-infected individuals
(NI) as described under Methods. Results are expressed as
means of duplicates. Negative samples were those rendering
OD values below NI baseline value 63 SD (dark grey zone).
Non-conclusive samples were those rendering OD values
between NI baseline value 63 SD and NI baseline 65 SD
(light grey zone). Samples indicated to the right were re-assayed
by dot-blot revealed using West-Fempto except for patient
P26, which was revealed using West-Pico chemiluminescent
substrate.
(TIF)
Figure S2 Cytokine kinetics in PBMC stimulated with
P2b protein. PBMC from patients with chronic Chagas’
disease Cardiomyopathy patients (CCC; n = 10) and non-
infected individuals (NI; n = 8) were cultured in the presence
of the indicated stimulus. Supernatants were collected on day 1,
2 and 6 and cytokines quantified by multiplex technology. The
Fold increase was calculated as: [(cytokine in stimulated
culture) - (cytokine in NS culture)]/(cytokine in NS culture),
where NS denotes non-stimulated cultured PBMCs. Each
symbol represents data from a single subject. The data were
analyzed by using the Mann-Whitney U Test, ***P,0.001,
**P,0.01, *P,0.05.
(TIF)
Figure S3 Cytokine kinetics in PBMC stimulated with
CP0 protein. PBMC from patients with chronic Chagas’
disease Cardiomyopathy patients (CCC; n = 10) and non-
infected individuals (NI; n = 8) were cultured in the presence
of the indicated stimulus. Supernatants were collected on day 1,
2 and 6 and cytokines quantified by multiplex technology. The
Fold increase was calculated as: [(cytokine in stimulated
culture) - (cytokine in NS culture)]/(cytokine in NS culture),
where NS denotes non-stimulated cultured PBMCs. Each
symbol represents data from a single subject. The data were
analyzed by using the Mann-Whitney U Test, ***P,0.001,
**P,0.01, *P,0.05.
(TIF)
Figure S4 Cytokine kinetics in PBMC stimulated with
T. cruzi lysate. PBMC from patients with chronic Chagas’
disease Cardiomyopathy patients (CCC; n = 10) and non-infected
individuals (NI; n = 8) were cultured in the presence of the
indicated stimulus. Supernatants were collected on day 1, 2 and 6
and cytokines quantified by multiplex technology. The Fold
increase was calculated as: [(cytokine in stimulated culture) -
(cytokine in NS culture)]/(cytokine in NS culture), where NS
denotes non-stimulated cultured PBMCs. Each symbol represents
data from a single subject. The data were analyzed by using the
Mann-Whitney U Test, ***P,0.001, **P,0.01, *P,0.05.
(TIF)
Figure S5 Cytokine kinetics in PBMC stimulated with
PHA. PBMC from patients with chronic Chagas’ disease
Cardiomyopathy patients (CCC; n = 10) and non-infected
individuals (NI; n = 8) were cultured in the presence of the
indicated stimulus. Supernatants were collected on day 1, 2
and 6 and cytokines quantified by multiplex technology. The
Fold increase was calculated as: [(cytokine in stimulated
culture) - (cytokine in NS culture)]/(cytokine in NS culture),
where NS denotes non-stimulated cultured PBMCs. Each
symbol represents data from a single subject. The data were
analyzed by using the Mann-Whitney U Test, ***P,0.001,
**P,0.01, *P,0.05.
(TIF)
Figure S6 Basal cytokine levels. PBMC from patients with
chronic Chagas’ disease Cardiomyopathy patients (CCC; n = 10)
and non-infected individuals (NI; n = 8) were cultured in media
without any stimulation. Supernatants were collected on days 1, 2
and 6 and cytokines were quantified by multiplex technology.
Each symbol represents data from a single subject. Statistical
analysis was performed by using the Mann-Whitney U Test,
***P,0.001, **P,0.01, *P,0.05.
(TIF)
Figure S7 Correlation between cytokine releases by
PBMC from CCC patients upon stimulation with P2b
and CP0 proteins. Results were expressed as the sum of
maximum fold increase (FI) for GM-CSF, IL-10 and TNF-a,
determined as indicated in Figure 2. Spearman’s correlation was
performed using GraphPad Prism and data is shown (r: 0.988, P,
0.0001).
(TIF)
Text S1 T. cruzi lineage identification by immunophe-
notyping.
(DOCX)
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